WHO says obesity is “chronic, progressive and relapsing disease” that affects more than 1 billion people globally,
LONDON: The World Health Organization has supported using weight-loss jabs to treat obesity, saying it is time to see the condition not just as a lifestyle problem but as a serious, long-term disease.
In new draft guidance, the agency urged countries to change their mindset and treat obesity as a chronic illness that demands proper medical care.
The WHO’s expert committee concluded that the popular GLP-1 drugs, first developed by Novo Nordisk and Eli Lilly, are part of the solution for the long-term treatment of obesity for patients with a body mass index (BMI) of 30 or above, alongside counselling on lifestyle and behaviour changes.
Reuters first reported that the WHO was likely to take this step in May this year.
In the draft guidelines, which were published online and are open for consultation until September 27, the WHO said the response to obesity was often shaped by outdated views that frame it as a lifestyle issue. Instead, it said it was a “chronic, progressive and relapsing disease” that affects more than 1 billion people globally in both high- and low-income countries, contributing to millions of preventable deaths.
It recommended using the drugs to treat obesity for the first time, calling it a critical step toward developing a global standard of care. It is developing separate guidelines for treating children and adolescents.
While the WHO’s draft guidelines only apply to people with a BMI above 30, in some high-income countries like the United States, the drugs are also recommended for people with a BMI of 27 to 30 and at least one weight-related medical condition.
Earlier this month, the WHO stopped short of adding the drugs as obesity treatments to its essential medicines list, a separate catalogue of the drugs that should be available in all functioning health systems.
It did add them for patients with type 2 diabetes – the disease they were originally developed to treat – combined with another health condition. The agency said this indicated which patients would most benefit from the costly therapies, adding that the high prices were limiting access to the medicines in low- and middle-income countries.
